Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Full or fractional third-dose COVID-19 booster vaccination in adults previously vaccinated with Sinovac/Butantan
RBR-4vmh6xgPhase 4Recruiting
- Sponsor
- CEPMI
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ChAdOx1 nCoV-19, tozinameran and coronavac in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by CEPMI. Started Mar 2022; status: recruiting.
02
Drugs
ChAdOx1 nCoV-19tozinamerancoronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on RBR-4vmh6xg.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-4vmh6xg.